Zoetis Inc. is an animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision animal health solutions. The company serves eight core species: dogs, cats, horses, cattle, swine, poultry, fish, and sheep. Its product portfolio spans seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. Zoetis operates in two segments: the United States and International, serving customers in multiple countries. Key customers include veterinarians, pet owners, and livestock producers. The company also provides contract manufacturing services through its Client Supply Services organization and offers human health diagnostics products. Incorporated in 2012, Zoetis was formerly a business unit of Pfizer Inc. Notable product lines include Simparica and Simparica Trio.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - Specialty & Generic Homepage zoetis.com
Sector Healthcare IR page investor.zoetis.com/home/default.aspx
Tags
animal health, veterinary medicine, vaccines, parasiticides, diagnostics, companion animals, livestock, biodevices, genetic testing, precision animal health, Simparica, Simparica Trio, Client Supply Services
Press page —

Metrics

Valuation  
Market cap $ 28.455B
Market cap (USD) $ 28.455B
P/E 11.88
PEG 1.46
P/BV 8.61
P/S 2.99
P/OCF 10.26
P/FCF 12.49
Dividend yield 0.01%
Turnover / mcap —
Returns  
ROE 66.0%
ROI 21.6%
ROIC 23.1%
Profit margin 28.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 8.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 274.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score 68.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 9.467B 9.256B 8.544B 8.08B 7.776B 6.675B 6.26B 5.825B 5.307B 4.888B 4.765B 4.785B 4.561B 4.336B
Net profit 2.673B 2.486B 2.344B 2.114B 2.037B 1.638B 1.5B 1.428B 864M 821M 339M 583M 504M 436M
Free cash flow 2.283B 2.298B 1.621B 1.326B 1.736B 1.673B 1.335B 1.452B 1.122B 497M 440M 446M 497M 328M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 125.82 162.93 197.37 146.55 244.03 165.5 132.35 85.54 72.04 53.53 47.92 43.03 32.69 30.78
Price performance 12m -0.23 -0.17 0.35 -0.4 0.47 0.25 0.55 0.19 0.35 0.12 0.11 0.32 0.06 -0.79

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 913M 998M 1.04B 1.09B 1.01B 1.13B 1.22B 1.3B 1.32B 1.59B
↳ YoY growth -2.6% +9.3% +3.8% +4.8% -6.7% +11.8% +7.2% +7.3% +0.9% +20.8%
↳ 5y CAGR +2.1% -1.9% +2.1% +1.6% +4.4% +4.0% +4.7% +3.9% +9.4%
Borrowings, current (USD) 0.00 0.00 9M 500M 604M 0.00 1.35B 3M 1.35B 0.00
Borrowings, non-current (USD) 4.47B 4.95B 6.44B 5.95B 6.6B 6.59B 6.55B 6.56B 5.22B 9.04B
Lease liabilities (USD) — — 200M 199M 203M 192M 229M 245M 233M 255M
Cash and deposits (USD) 727M 1.56B 1.6B 1.93B 3.6B 3.49B 3.58B 2.04B 1.99B 2.31B
Intangible assets (USD) 1.23B 1.27B 2.05B 1.89B 1.71B 1.47B 1.38B 1.34B 1.13B 998M
Right-of-use assets (USD) — — 200M 189M 192M 181M 220M 230M 219M 288M
Net debt (borrowings + leases - cash) (USD) 3.74B 3.39B 5.05B 4.71B 3.8B 3.3B 4.55B 4.77B 4.82B 6.99B
Cash flow detail
Operating cash flow (USD) 713M 1.35B 1.79B 1.8B 2.13B 2.21B 1.91B 2.35B 2.95B 2.9B
Purchases of property, plant and equipment (USD) -216M -224M -338M -460M -453M -477M -586M -732M -655M -621M
Purchases of intangible assets (USD) 0.00 — — — — — — — — —
Change in receivables (cash effect) (USD) 15M -50M -67M -69M 74M -155M -137M -102M -61M -236M
Change in inventories (cash effect) (USD) -101M 19M 61M -104M -346M -366M -486M -361M -40M -199M
Change in payables (cash effect) (USD) -28M -10M 37M -10M 147M -17M -29M 13M 31M 46M
Share buybacks (cash effect) (USD) -300M -500M -698M -626M -250M -743M -1.59B -1.09B -1.86B -3.24B
Interest paid (cash effect) (USD) -165M -167M -190M -247M -257M -253M -242M -295M -274M -261M
Income taxes paid (cash effect) (USD) -408M -455M -336M -418M -418M -548M -638M -754M -892M -715M
Share-based compensation (USD) 37M 44M 53M 67M 59M 58M 62M 60M 74M 83M
Operating cash flow before change in receivables (USD) 698M 1.4B 1.86B 1.86B 2.05B 2.37B 2.05B 2.46B 3.01B 3.14B
Free cash flow (OCF - PPE - intangibles) (USD) 497M 1.12B 1.45B 1.34B 1.67B 1.74B 1.33B 1.62B 2.3B 2.28B
Income detail
Research and development expense (USD) 376M 382M 432M 457M 463M 508M 539M 614M 686M 698M
↳ 5y CAGR -2.5% -1.4% +1.6% +2.9% +4.9% +6.2% +7.1% +7.3% +8.5% +8.6%
Total comprehensive income (USD) 840M 957M 1.3B 1.4B 1.63B 2B 2.06B 2.32B 2.4B 2.78B
Comprehensive income to owners (USD) 843M 957M 1.3B 1.4B 1.63B 2B 2.06B 2.32B 2.39B 2.78B
Reported Feb 16, 2017 Feb 15, 2018 Feb 14, 2019 Feb 13, 2020 Feb 16, 2021 Feb 15, 2022 Feb 14, 2023 Feb 13, 2024 Feb 13, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

◦U.S. segment revenue: $1.2 billion, decreased 6% reported and organic operational

◦International segment revenue: $1.1 billion, increased 4% reported and organic operational basis

•Net Income: $591 million, decreased 18% reported

•Adjusted net income: $720 million, decreased 5% reported and 7% organic operational

•Diluted EPS: $1.44, decreased 12% reported

•Adjusted diluted EPS: $1.75, increased 3% reported and 1% organic operational

PARSIPPANY, N.J. – November 5, 2026 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026.

"Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio," said Kristin Peck, Chief Executive Officer of Zoetis. "We remain focused on defending our position and directing our resources where they can have the greatest impact.

Home NEWS & INSIGHTS MEDIA STATEMENT DETAILS

Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance

November 5, 2026

Download(opens in new window)

Third Quarter 2026 Highlights

  • Revenue: $2.4 billion**,** decreased 1% reported and organic operational1
    • U.S. segment revenue: $1.2 billion, decreased 6% reported and organic operational
    • International segment revenue: $1.1 billion, increased 4% reported and organic operational basis
  • Net Income: $591 million**,** decreased 18% reported
  • Adjusted net income: $720 million**,** decreased 5% reported and 7% organic operational
  • Diluted EPS: $1.44, decreased 12% reported
  • Adjusted diluted EPS: $1.75, increased 3% reported and 1% organic operational

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc . (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026.

"Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio," said Kristin Peck, Chief Executive Officer of Zoetis. "We remain focused on defending our position and directing our resources where they can have the greatest impact. And with the scale, expertise, and pipeline to keep setting the pace of innovation in animal health, we are confident in our ability to create long-term value for customers and shareholders."

**THIRD QUARTER 2026 FINANCIAL RESULTS
**The company reported revenue of $2.4 billion for the third quarter of 2026, a decrease of 1% on a reported and an organic operational1 basis compared with the third quarter of 2025. Net income for the third quarter of 2026 was $591 million, decreasing 18% on a reported basis. Diluted EPS was $1.44, decreasing 12% on a reported basis.

Adjusted net income2 for the third quarter of 2026 was $720 million, decreasing 5% on a reported basis and 7% on an organic operational basis. Adjusted diluted EPS was $1.75, increasing 3% on a reported basis and 1% on an organic operational basis. Adjusted net income for the third quarter of 2026 excludes the net impact of $129 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

**THIRD QUARTER 2026 SEGMENT HIGHLIGHTS
**Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the third quarter of 2026:

  • Revenue in the U.S. segment was $1.2 billion, decreasing 6% on both a reported and an organic operational basis relative to the third quarter of 2025. Companion animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition. Livestock revenue increased 5% on both a reported and organic operational basis in the quarter, supported by strength across cattle, swine and poultry.
  • Revenue in the International segment was $1.1 billion, increasing 4% on both a reported and an organic operational basis compared with the third quarter of 2025. Companion animal revenue increased 1% on a reported basis and remained flat on an organic operational basis, led by parasiticides and osteoarthritis (OA) pain, while partially offset by lower sales of key dermatology products. Livestock revenue increased 8% on a reported basis and 9% on an organic operational basis, driven by growth in cattle and fish.

**INNOVATION PIPELINE ADVANCEMENTS AND PORTFOLIO UPDATES
**Zoetis continued to advance innovation across its diversified portfolio, and remains on track for expected 2026 product approvals, with select approvals anticipated in 2027 now expected in Q4 2026.

**Regulatory Approvals and Portfolio Expansion
**In October, Zoetis received U.S. Food and Drug Administration (FDA) approval for Convenia® RTU for Dogs, a long-acting antibacterial injection for dogs. This is the second major market approval this year, with both achieved ahead of the expected timelines, and expands Zoetis' portfolio of therapies designed to broaden treatment options for dogs. Convenia RTU for Dogs is expected to be available to veterinarians in the first quarter of 2027.

Zoetis launched Lenivia® for dogs in Great Britain and received Swiss approval for Portela® for cats, expanding access to long-acting osteoarthritis pain relief that can last up to three months with a single injection.

During the quarter, Simparica Trio® received U.S. FDA Emergency Use Authorization (EUA) for the treatment of New World screwworm infestations in dogs and puppies. The authorization adds to Zoetis' existing response, including Dectomax and Dectomax®-CA1 for other species at risk.

Additional approvals from the quarter include:

  • Fostera® PRRS Needle-free microdose was approved in the U.S. and Mexico to help protect pigs against porcine reproductive and respiratory syndrome.
  • Vanguard® B Oral received an additional claim in Brazil to help protect dogs against Bordetella__bronchiseptica.
  • Vanguard® crLyme received an additional claim in Canada to help protect dogs against subclinical arthritis caused by Borrelia burgdorferi.
  • Alfaxan®Multidose4% was approved in Japan and Mexico for sedation of cats.

New Peer-Reviewed Research and Zoetis Medical Hub Launch

  • A peer-reviewed study published in Parasites & Vectors found that dogs treated with Simparica Trio had significantly lower average heartworm counts than dogs treated with NexGard ® Plus, with few dogs in the Simparica Trio group having adult heartworms at the study's conclusion.
  • The study is available through the newly launched Zoetis Medical Hub , which brings together medical expertise and peer-reviewed research.

**FULL YEAR 2026 FINANCIAL GUIDANCE
**Zoetis is providing updated guidance:

  • Narrowed revenue to a range of $9.220 billion to $9.320 billion (organic operational growth of (2)% to (1)%)
  • Raised adjusted net income to a range of $2.600 billion to $2.640 billion (organic operational growth of (7)% to (5)%)
  • Raised adjusted diluted EPS to a range of $6.25 to $6.35

This guidance reflects foreign exchange rates as of October 20, 2026. Additional details on guidance, including reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures, are included in the financial tables and will be discussed on the company's conference call.

**WEBCAST & CONFERENCE CALL DETAILS
**Zoetis will host a webcast and conference call November 5, 2026, at 8:30 a.m. ET to review third quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations . A replay of the webcast will be available following the event.

**About Zoetis
**Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com .

_1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
_2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

_DISCLOSURE NOTICES
_Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at _www.sec.gov _, www.zoetis.com , or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com .

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com , as well as on LinkedIn , Facebook , X (formerly Twitter) and YouTube . We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

_ZTS-COR
__ZTS-IR
_ZTS-FIN

ZOETIS INC.CONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)(millions of dollars, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 % Change 2026 2025 % Change
Revenue $ 2,391 $ 2,422 (1 ) $ 7,121 $ 7,094 —
Costs and expenses:
Cost of sales 698 697 — 2,012 1,979 2
Selling, general and administrative expenses 582 582 — 1,762 1,770 —
Research and development expenses 174 175 (1 ) 527 503 5
Amortization of intangible assets 31 32 (3 ) 93 97 (4 )
Restructuring charges and certain acquisition and divestiture-related costs 43 4 * 142 34 *
Interest expense, net of capitalized interest 62 58 7 185 165 12
Other (income)/deductions–net 72 (12 ) * 47 (25 ) *
Income before provision for taxes on income 729 886 (18 ) 2,353 2,571 (8 )
Provision for taxes on income 138 165 (16 ) 470 522 (10 )
Net income before allocation to noncontrolling interests 591 721 (18 ) 1,883 2,049 (8 )
Less: Net income/(loss) attributable to noncontrolling interests — — * — — *
Net income attributable to Zoetis Inc. $ 591 $ 721 (18 ) $ 1,883 $ 2,049 (8 )
Earnings per share attributable to Zoetis—basic $ 1.44 $ 1.63 (12 ) $ 4.51 $ 4.60 (2 )
Earnings per share attributable to Zoetis—diluted $ 1.44 $ 1.63 (12 ) $ 4.51 $ 4.60 (2 )
Weighted-average shares used to calculate earnings per share
Basic 411.6 442.9 417.1 445.2
Diluted 411.6 443.2 417.3 445.6
* Calculation not meaningful.
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Three Months Ended September 30, 2026
GAAPReported PurchaseAccountingAdjustments AcquisitionandDivestiture-RelatedCosts(1) CertainSignificantItems(2) Non-GAAPAdjusted(a)
Cost of sales $ 698 $ (1 ) $ — $ (3 ) $ 694
Gross profit 1,693 1 — 3 1,697
Selling, general and administrative expenses 582 (3 ) — (8 ) 571
Amortization of intangible assets 31 (27 ) — — 4
Restructuring charges and certain acquisition and divestiture-related costs 43 — (2 ) (41 ) —
Other (income)/deductions–net 72 — — (81 ) (9 )
Income before provision for taxes on income 729 31 2 133 895
Provision for taxes on income 138 7 — 30 175
Net income attributable to Zoetis 591 24 2 103 720
Earnings per common share attributable to Zoetis–diluted 1.44 0.06 — 0.25 1.75
Three Months Ended September 30, 2025
GAAPReported PurchaseAccountingAdjustments AcquisitionandDivestiture-RelatedCosts(1) CertainSignificantItems(2) Non-GAAPAdjusted(a)
Cost of sales $ 697 $ (1 ) $ — $ (1 ) $ 695
Gross profit 1,725 1 — 1 1,727
Selling, general and administrative expenses 582 (3 ) — (7 ) 572
Research and development expenses 175 (1 ) — — 174
Amortization of intangible assets 32 (27 ) — — 5
Restructuring charges and certain acquisition and divestiture-related costs 4 — — (4 ) —
Other (income)/deductions–net (12 ) — — 4 (8 )
Income before provision for taxes on income 886 32 — 8 926
Provision for taxes on income 165 8 — (1 ) 172
Net income attributable to Zoetis 721 24 — 9 754
Earnings per common share attributable to Zoetis–diluted 1.63 0.05 — 0.02 1.70
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Nine Months Ended September 30, 2026
GAAPReported PurchaseAccountingAdjustments AcquisitionandDivestiture-RelatedCosts(1) CertainSignificantItems(2) Non-GAAPAdjusted(a)
Cost of sales $ 2,012 $ (3 ) $ — $ (8 ) $ 2,001
Gross profit 5,109 3 — 8 5,120
Selling, general and administrative expenses 1,762 (5 ) — (15 ) 1,742
Research and development expenses 527 (1 ) — — 526
Amortization of intangible assets 93 (80 ) — — 13
Restructuring charges and certain acquisition and divestiture-related costs 142 — (6 ) (136 ) —
Other (income)/deductions–net 47 — — (82 ) (35 )
Income before provision for taxes on income 2,353 89 6 241 2,689
Provision for taxes on income 470 20 1 51 542
Net income attributable to Zoetis 1,883 69 5 190 2,147
Earnings per common share attributable to Zoetis–diluted 4.51 0.17 0.01 0.45 5.14
Nine Months Ended September 30, 2025
GAAPReported PurchaseAccountingAdjustments AcquisitionandDivestiture-RelatedCosts(1) CertainSignificantItems(2) Non-GAAPAdjusted(a)
Cost of sales $ 1,979 $ (3 ) $ — $ (3 ) $ 1,973
Gross profit 5,115 3 — 3 5,121
Selling, general and administrative expenses 1,770 (8 ) — (22 ) 1,740
Research and development expenses 503 (2 ) — — 501
Amortization of intangible assets 97 (84 ) — — 13
Restructuring charges and certain acquisition and divestiture-related costs 34 — (1 ) (33 ) —
Other (income)/deductions–net (25 ) — — (4 ) (29 )
Income before provision for taxes on income 2,571 97 1 62 2,731
Provision for taxes on income 522 23 — 8 553
Net income attributable to Zoetis 2,049 74 1 54 2,178
Earnings per common share attributable to Zoetis–diluted 4.60 0.17 — 0.12 4.89
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATIONCERTAIN LINE ITEMS(UNAUDITED)(millions of dollars)
(1) Acquisition and divestiture-related costs include the following:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
Acquisition-related costs(a) $ 2 $ — $ 6 $ 1
Total acquisition and divestiture-related costs—pre-tax 2 — 6 1
Income taxes(b) — — 1 —
Total acquisition and divestiture-related costs—net of tax $ 2 $ — $ 5 $ 1
(a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
(2) Certain significant items include the following:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
Other restructuring charges and cost-reduction/productivity initiatives(a) $ 30 $ 4 $ 125 $ 11
Business process transformation program(b) 7 8 18 26
Certain asset impairment charges(c) 89 — 89 27
Net loss on sale of business(d) — — — 3
Other 7 (4 ) 9 (5 )
Total certain significant items—pre-tax 133 8 241 62
Income taxes(e) 30 (1 ) 51 8
Total certain significant items—net of tax $ 103 $ 9 $ 190 $ 54
(a) For the three and nine months ended September 30, 2026, primarily driven by employee termination costs under a comprehensive cost and productivity program, with the nine-month period also reflecting employee termination costs from additional organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs. For the three and nine months ended September 30, 2025, primarily related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.
(c) For the three and nine months ended September 30, 2026, represents impairment charges on in-process research and development assets, acquired from PetMedix in 2023, resulting from updated estimates of development and commercial assumptions, included in Other (income)/deductions–net, as well as charges related to the exit of certain sites, included in Restructuring charges and certain acquisition and divestiture-related costs. For the three and nine months ended September 30, 2025, represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio, included in Other (income)/deductions–net.
(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.
(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
ZOETIS INC.ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)(UNAUDITED)(millions of dollars)
Three Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b) Divestitures OrganicOperational(c)
Adjusted cost of sales $ 694 $ 695 — % — % — %
as a percent of revenue 29.0 % 28.7 % NA NA NA
Adjusted SG&A expenses 571 572 — % — % — %
Adjusted R&D expenses 174 174 — % — % — %
Adjusted net income 720 754 (5 )% 2 % (7 )% — % (7 )%
Nine Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b) Divestitures OrganicOperational(c)
Adjusted cost of sales $ 2,001 $ 1,973 1 % 3 % (2 )%
as a percent of revenue 28.1 % 27.8 % NA NA NA
Adjusted SG&A expenses 1,742 1,740 — % 1 % (1 )%
Adjusted R&D expenses 526 501 5 % 1 % 4 %
Adjusted net income 2,147 2,178 (1 )% 2 % (3 )% — % (3 )%
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.2026 GUIDANCE
Selected Line Items(millions of dollars, except per share amounts) Full Year 2026as of November 5, 2026 Full Year 2026as of August 6, 2026(Prior Guidance)
Revenue $9,220 to $9,320 $9,120 to $9,320
Organic operational results(a) (2)% to (1)% (3)% to (1)%
Adjusted cost of sales as a percentage of revenue(b) Approximately 29.0% Approximately 29.0%
Adjusted SG&A expenses(b) $2,340 to $2,370 $2,330 to $2,380
Adjusted R&D expenses(b) $705 to $715 $720 to $730
Adjusted interest expense and other (income)/deductions-net(b) Approximately $215 Approximately $215
Effective tax rate on adjusted income(b) Approximately 20% Approximately 20.5%
Adjusted diluted EPS(b) $6.25 to $6.35 $6.15 to $6.25
Adjusted net income(b) $2,600 to $2,640 $2,570 to $2,620
Organic operational results(a)(c) (7)% to (5)% (9)% to (5)%
Certain significant items and acquisition and divestiture-related costs(d) Approximately $210 Approximately $150
Reported diluted EPS $5.50 to $5.60 $5.55 to $5.65
The guidance reflects foreign exchange rates as of October 20, 2026.
Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows:
(millions of dollars, except per share amounts) Reported Certain significant items and acquisition and divestiture-related costs(d) Purchase accounting Adjusted(b)
Cost of sales as a percentage of revenue ~ 29.1% ~ (0.1%) ~ 29.0%
SG&A expenses $2,373 to $2,403 ~ $(22) ~ $(11) $2,340 to $2,370
R&D expenses $707 to $717 ~ $(2) $705 to $715
Interest expense and other (income)/deductions-net ~ $215 ~ $215
Effective tax rate ~ 20% ~ 20%
Diluted EPS $5.50 to $5.60 ~ $0.53 ~ $0.22 $6.25 to $6.35
Net income attributable to Zoetis $2,300 to $2,340 ~ $210 ~ $90 $2,600 to $2,640
(a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.
ZOETIS INC.CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES(UNAUDITED)(millions of dollars)
Three Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b) Divestitures OrganicOperational(c)
Revenue:
Companion Animal $ 1,565 $ 1,650 (5 )% — % (5 )% — % (5 )%
Livestock 797 746 7 % 1 % 6 % (1 )% 7 %
Contract Manufacturing & Human Health 29 26 12 % (3 )% 15 % — % 15 %
Total Revenue $ 2,391 $ 2,422 (1 )% 1 % (2 )% (1 )% (1 )%
U.S.:
Companion Animal $ 980 $ 1,069 (8 )% — % (8 )% — % (8 )%
Livestock 266 253 5 % — % 5 % — % 5 %
Total U.S. Revenue $ 1,246 $ 1,322 (6 )% — % (6 )% — % (6 )%
International:
Companion Animal $ 585 $ 581 1 % 1 % — % — % — %
Livestock 531 493 8 % 2 % 6 % (3 )% 9 %
Total International Revenue $ 1,116 $ 1,074 4 % 1 % 3 % (1 )% 4 %
Companion Animal:
Dogs and Cats $ 1,492 $ 1,581 (6 )% — % (6 )%
Horses 73 69 6 % — % 6 %
Total Companion Animal Revenue $ 1,565 $ 1,650 (5 )% — % (5 )%
Livestock:
Cattle $ 439 $ 415 6 % 1 % 5 %
Swine 120 116 3 % 1 % 2 %
Poultry 108 106 2 % (1 )% 3 %
Fish 98 80 23 % 5 % 18 %
Sheep and other 32 29 10 % 4 % 6 %
Total Livestock Revenue $ 797 $ 746 7 % 1 % 6 %
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES(UNAUDITED)(millions of dollars)
Nine Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b) Divestitures OrganicOperational(c)
Revenue:
Companion Animal $ 4,792 $ 4,981 (4 )% 1 % (5 )% — % (5 )%
Livestock 2,248 2,024 11 % 3 % 8 % (2 )% 10 %
Contract Manufacturing & Human Health 81 89 (9 )% — % (9 )% — % (9 )%
Total Revenue $ 7,121 $ 7,094 — % 1 % (1 )% — % (1 )%
U.S.:
Companion Animal $ 2,889 $ 3,218 (10 )% — % (10 )% — % (10 )%
Livestock 713 643 11 % — % 11 % — % 11 %
Total U.S. Revenue $ 3,602 $ 3,861 (7 )% — % (7 )% — % (7 )%
International:
Companion Animal $ 1,903 $ 1,763 8 % 4 % 4 % — % 4 %
Livestock 1,535 1,381 11 % 4 % 7 % (2 )% 9 %
Total International Revenue $ 3,438 $ 3,144 9 % 4 % 5 % (1 )% 6 %
Companion Animal:
Dogs and Cats $ 4,569 $ 4,777 (4 )% 2 % (6 )%
Horses 223 204 9 % 2 % 7 %
Total Companion Animal Revenue $ 4,792 $ 4,981 (4 )% 1 % (5 )%
Livestock:
Cattle $ 1,221 $ 1,079 13 % 2 % 11 %
Swine 360 339 6 % 3 % 3 %
Poultry 341 316 8 % 1 % 7 %
Fish 247 216 14 % 6 % 8 %
Sheep and other 79 74 7 % 6 % 1 %
Total Livestock Revenue $ 2,248 $ 2,024 11 % 3 % 8 %
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS(UNAUDITED)(millions of dollars)
Three Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Divestitures OrganicOperational(a)
Total International $ 1,116 $ 1,074 4 % 1 % (1 )% 4 %
Australia 104 92 13 % 9 % — % 4 %
Brazil 114 105 9 % 6 % — % 3 %
Canada 70 76 (8 )% — % (10 )% 2 %
Chile 34 33 3 % (2 )% — % 5 %
China 61 51 20 % 6 % — % 14 %
France 37 35 6 % (3 )% (1 )% 10 %
Germany 51 62 (18 )% (2 )% (1 )% (15 )%
Italy 30 34 (12 )% (2 )% — % (10 )%
Japan 26 34 (24 )% (6 )% — % (18 )%
Mexico 49 42 17 % 10 % — % 7 %
Spain 37 36 3 % (2 )% (2 )% 7 %
United Kingdom 75 79 (5 )% 1 % (2 )% (4 )%
Other developed markets 183 165 11 % 1 % — % 10 %
Other emerging markets 245 230 7 % (2 )% (1 )% 10 %
Nine Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Divestitures OrganicOperational(a)
Total International $ 3,438 $ 3,144 9 % 4 % (1 )% 6 %
Australia 287 254 13 % 10 % — % 3 %
Brazil 307 279 10 % 9 % — % 1 %
Canada 215 217 (1 )% 1 % (7 )% 5 %
Chile 106 102 4 % 2 % (1 )% 3 %
China 186 173 8 % 6 % — % 2 %
France 114 116 (2 )% 3 % (1 )% (4 )%
Germany 179 174 3 % 4 % (1 )% — %
Italy 109 101 8 % 5 % (1 )% 4 %
Japan 102 109 (6 )% (6 )% (1 )% 1 %
Mexico 144 116 24 % 14 % — % 10 %
Spain 120 105 14 % 4 % (2 )% 12 %
United Kingdom 225 234 (4 )% 2 % (1 )% (5 )%
Other developed markets 539 473 14 % 5 % (1 )% 10 %
Other emerging markets 805 691 16 % — % (1 )% 17 %
(a) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.SEGMENT(a) EARNINGS(UNAUDITED)(millions of dollars)
Three Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b)
U.S.:
Revenue $ 1,246 $ 1,322 (6 )% — % (6 )%
Cost of Sales 222 222 — % — % — %
Gross Profit 1,024 1,100 (7 )% — % (7 )%
Gross Margin 82.2 % 83.2 %
Operating Expenses 194 201 (3 )% — % (3 )%
Other (income)/deductions-net — — * * *
U.S. Earnings $ 830 $ 899 (8 )% — % (8 )%
International:
Revenue $ 1,116 $ 1,074 4 % 1 % 3 %
Cost of Sales 347 342 1 % — % 1 %
Gross Profit 769 732 5 % 2 % 3 %
Gross Margin 68.9 % 68.2 %
Operating Expenses 169 169 — % 1 % (1 )%
Other (income)/deductions-net — — * * *
International Earnings $ 600 $ 563 7 % 2 % 5 %
Total Reportable Segments $ 1,430 $ 1,462 (2 )% 1 % (3 )%
Other business activities(c) (134 ) (143 ) (6 )%
Reconciling Items:
Corporate(d) (303 ) (304 ) — %
Purchase accounting adjustments(e) (31 ) (32 ) (3 )%
Acquisition and divestiture-related costs(f) (2 ) — *
Certain significant items(g) (133 ) (8 ) *
Other unallocated(h) (98 ) (89 ) 10 %
Total Earnings(i) $ 729 $ 886 (18 )%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.
ZOETIS INC.SEGMENT(a) EARNINGS(UNAUDITED)(millions of dollars)
Nine Months Ended
September 30, % Change
2026 2025 ReportedChange ForeignExchange Operational(b)
U.S.:
Revenue $ 3,602 $ 3,861 (7 )% — % (7 )%
Cost of Sales 630 629 — % — % — %
Gross Profit 2,972 3,232 (8 )% — % (8 )%
Gross Margin 82.5 % 83.7 %
Operating Expenses 608 624 (3 )% — % (3 )%
Other (income)/deductions-net — — * * *
U.S. Earnings $ 2,364 $ 2,608 (9 )% — % (9 )%
International:
Revenue $ 3,438 $ 3,144 9 % 4 % 5 %
Cost of Sales 1,021 958 7 % 5 % 2 %
Gross Profit 2,417 2,186 11 % 4 % 7 %
Gross Margin 70.3 % 69.5 %
Operating Expenses 516 503 3 % 4 % (1 )%
Other (income)/deductions-net 1 1 — % * *
International Earnings $ 1,900 $ 1,682 13 % 4 % 9 %
Total Reportable Segments $ 4,264 $ 4,290 (1 )% 1 % (2 )%
Other business activities(c) (410 ) (405 ) 1 %
Reconciling Items:
Corporate(d) (933 ) (906 ) 3 %
Purchase accounting adjustments(e) (89 ) (97 ) (8 )%
Acquisition and divestiture-related costs(f) (6 ) (1 ) *
Certain significant items(g) (241 ) (62 ) *
Other unallocated(h) (232 ) (248 ) (6 )%
Total Earnings(i) $ 2,353 $ 2,571 (8 )%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.

Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
[email protected]

Laura Panza
1-973-975-5176 (o)
[email protected]

Investor Contacts:
Mathieu Aussermeier
1-862-460-0181 (o)
[email protected]

Nick Soonthornchai
1-973-443-2792 (o)
[email protected]

Source: Zoetis Inc.

SHARE:

Visit Zoetis on Facebook Visit Zoetis on X Visit Zoetis on LinkedIn Visit Zoetis on YouTube Share Email

Zoetis News Home

Copyright © Zoetis 2013-2026 All rights reserved. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Opens in new window

Copy link

✓

Thanks for sharing!

Find any service

AddToAny

More…

This website uses cookies and other tracking technologies, including those provided by third parties, for essential site functionality, analytics, personalization, and targeted advertising. You can choose to “Accept All”, “Reject All”, or “Customize” your preferences for non-essential technologies. Declining or customizing tracking to reject optional tracking does not otherwise affect the collection, use, storage, and disclosure of your data in other contexts as described in the terms of our Privacy Center .

Customize Reject All Accept All

Company Logo

Cookie Preference Center

Cookie Preference Center

  • Cookie Notice

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Cookie Notice

Our websites use cookies and other tracking technologies (“Cookies”) as described below. For more details, please see the description of each type of Cookie we use, below. Residents of some jurisdictions have the right to opt out of the sale/sharing of their personal information and the processing of their personal information for targeted advertising purposes. To opt out of sale, sharing, and targeted advertising, you can click “Reject All” below. For more details about our privacy practices, see our Privacy Policy .

Strictly Necessary Cookies

Always Active

These are cookies that are essential for the operation of our website. These cookies remember information you have entered on forms when you navigate to different pages during a web browser session, identify you as being logged in to our website, and perform other functions necessary for the operation of the website.

Cookies Details

Performance Cookies

Performance Cookies

These cookies allow us to recognize and count the number of visitors and to see how visitors move around on our website when they are using it. These cookies help us to improve the way the website works, for example, by ensuring that users are finding what they are looking for easily. These cookies provide statistics on how our website is used, help us improve the website by measuring any errors that occur, and support other website performance improvements.

Cookies Details

Functional Cookies

Functional Cookies

These are cookies that are used to recognize you when you return to our website. This enables us to personalize our content for you, greet you by name, remember if we have already asked you if you want to fill in a survey, and remember your preferences, for example your choice of language or region.

Cookies Details

Targeting Cookies

Targeting Cookies

These are cookies recording a user's visit to a website, the individual pages visited and the links followed. If the cookie is set by a third party (for example, an advertising network) which also monitors traffic on other websites, this type of cookie may also be used to track a user's movements across different websites and to create profiles of their general online behavior. Information collected by tracking cookies is commonly used to serve users with targeted online advertising.

Cookies Details

Back Button

Cookie List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Confirm My Choices

Reject All Accept All

Powered by Onetrust

Home NEWS & INSIGHTS MEDIA STATEMENT DETAILS

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

October 20, 2026

Download(opens in new window)

Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional

  • Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1
  • Administration at the veterinary clinic helps dog owners avoid the day-to-day challenge of giving oral antibiotics at home and reduces the risk of missed or irregular doses.
  • Higher concentration of an antibacterial agent can deliver the same dose of treatment in a smaller volume, helping make single-injection treatment more practical for dogs of all sizes.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Convenia® RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs.

For many families, administering oral antibiotics daily for one to two weeks can be difficult, especially when a dog resists medication or a household schedule makes routine timing hard to maintain. Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections in dogs and is administered by a veterinary health professional, supporting complete dose compliance.

“Anyone who has tried to give a dog pills for a week or two knows how challenging it can be to stay on schedule. Convenia® (cefovecin sodium) has been a veterinarian-trusted treatment for susceptible bacterial skin infections for over a decade and has helped remove the burden of continued and accurate dosing that is typically required with oral antibiotics,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. “With Convenia RTU for Dogs, we are building on the established Convenia portfolio with a formulation designed for use in dogs of all sizes.”

Convenia RTU for Dogs joins Convenia, an injectable medication approved by the FDA in 2008 to treat susceptible bacterial skin infections in cats and dogs. Because the Convenia RTU for Dogs formulation is more concentrated, it can deliver the same dose in a smaller volume making single-injection treatment easier and more practical for dogs of all sizes.

The addition of this product to Zoetis’ trusted dermatology portfolio underscores the ongoing commitment to providing treatments that are safe, effective and accessible for dogs of all sizes.

Clinical and real-world experience

Convenia RTU for Dogs is bioequivalent to Convenia, which has a level of trust with both veterinarians and pet owners as well as an efficacy record with 18 years of real-world experience.2 Both products share reliable efficacy in a single dose, with 86% of dogs in a study having needed just one injection of cefovecin to resolve their bacterial skin infection.3 To support the registration of Convenia globally, over 125 studies, including safety studies and significant microbiological isolate studies, were conducted.4

“I really believe that we, as veterinarians, underestimate adherence to our recommendations for antibiotic therapy. Our clients lead very busy lives and sometimes it’s difficult to remember who gave the correct dose and when it was given,” said Dr. Valerie A. Fadok, DVM, PhD, Diplomate, ACVD. “Medications that require twice or three times daily administration are often associated with poor compliance. If an antibiotic is medically appropriate, giving it by injection ensures compliance, and reduces the likelihood of resistance.”

Why dose compliance matters

In two canine studies, only 27% of dog owners administered the prescribed medication at the correct time intervals during short-term antibiotic treatment.5 Missing doses of oral antibiotics can compromise treatment success, undermine efficacy and potentially contribute to antibiotic resistance.6

About Convenia® RTU for Dogs (cefovecin injectable suspension)

Convenia RTU for Dogs (cefovecin injectable suspension) is a long-acting treatment for susceptible bacterial skin infections in dogs, administered by subcutaneous injection in a veterinary clinic. See additional information here . Convenia RTU for Dogs is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus pseudintermedius and Streptococcus canis (Group G).

Convenia RTU for Dogs is expected to be available to veterinarians in Q1 2027 as part of Zoetis’ expanding portfolio of products designed to broaden treatment options for all dogs, especially medium to large breeds.

IMPORTANT SAFETY INFORMATION ABOUT CONVENIA RTU FOR DOGS:

People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Convenia RTU for Dogs. Convenia RTU for Dogs should not be used in cats due to risk of toxicity. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins. Side effects include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information here , a direct URL.

About Convenia® (cefovecin sodium)

Convenia (cefovecin sodium) was the first FDA approved long-acting antibacterial treatment for susceptible bacterial skin infections in dogs and cats, administered by subcutaneous injection.2 Convenia is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus pseudintermedius (previously called Staphylococcus intermedius) and Streptococcus canis (Group G). It is also indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

IMPORTANT SAFETY INFORMATION ABOUT CONVENIA: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Convenia. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information at ConveniaPI.com .

About Zoetis

Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com .

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , www.zoetis.com , or on request from Zoetis.

_ZTS-COR
__ZTS-IR
__ZTS-CA
_ZTS-PS

1Nationwide, Most Common Medical Conditions that Prompt Veterinary Visits- 2022, April 13, 2023, Accessed October 20, 2026. https://news.nationwide.com/top-common-conditions-that-prompt-veterinary-visits/

2Convenia. Prescribing information. Zoetis Inc.; updated 2022.

3Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc. 2008; 233(3):433-439. doi:10.2460/javma.233.3.433.

4Zoetis, Inc. Data on file, 2025.

5Maddison, JE. Medication compliance in small animal practice. Vet Ir J, 2011; 39.

6Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther. 2006;29(6):501-511. doi:10.1111/j.1365-2885.2006.00801

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2026 Zoetis Services LLC. All rights reserved. AIF-00991

Media Contacts:    
Leah Coyle
862-202-3560 (c)    
[email protected]

Jennifer Albano
862-399-0810 (o)
[email protected]

Investor Contacts:   
Mathieu Aussermeier
862-460-0181 (o)
[email protected]

Nick Soonthornchai
973-443-2792 (o)
[email protected]

Source: Zoetis Inc.

SHARE:

Visit Zoetis on Facebook Visit Zoetis on X Visit Zoetis on LinkedIn Visit Zoetis on YouTube Share Email

Zoetis News Home

Copyright © Zoetis 2013-2026 All rights reserved. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Opens in new window

Copy link

✓

Thanks for sharing!

Find any service

AddToAny

More…

This website uses cookies and other tracking technologies, including those provided by third parties, for essential site functionality, analytics, personalization, and targeted advertising. You can choose to “Accept All”, “Reject All”, or “Customize” your preferences for non-essential technologies. Declining or customizing tracking to reject optional tracking does not otherwise affect the collection, use, storage, and disclosure of your data in other contexts as described in the terms of our Privacy Center .

Customize Reject All Accept All

Company Logo

Cookie Preference Center

Cookie Preference Center

  • Cookie Notice

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Cookie Notice

Our websites use cookies and other tracking technologies (“Cookies”) as described below. For more details, please see the description of each type of Cookie we use, below. Residents of some jurisdictions have the right to opt out of the sale/sharing of their personal information and the processing of their personal information for targeted advertising purposes. To opt out of sale, sharing, and targeted advertising, you can click “Reject All” below. For more details about our privacy practices, see our Privacy Policy .

Strictly Necessary Cookies

Always Active

These are cookies that are essential for the operation of our website. These cookies remember information you have entered on forms when you navigate to different pages during a web browser session, identify you as being logged in to our website, and perform other functions necessary for the operation of the website.

Cookies Details

Performance Cookies

Performance Cookies

These cookies allow us to recognize and count the number of visitors and to see how visitors move around on our website when they are using it. These cookies help us to improve the way the website works, for example, by ensuring that users are finding what they are looking for easily. These cookies provide statistics on how our website is used, help us improve the website by measuring any errors that occur, and support other website performance improvements.

Cookies Details

Functional Cookies

Functional Cookies

These are cookies that are used to recognize you when you return to our website. This enables us to personalize our content for you, greet you by name, remember if we have already asked you if you want to fill in a survey, and remember your preferences, for example your choice of language or region.

Cookies Details

Targeting Cookies

Targeting Cookies

These are cookies recording a user's visit to a website, the individual pages visited and the links followed. If the cookie is set by a third party (for example, an advertising network) which also monitors traffic on other websites, this type of cookie may also be used to track a user's movements across different websites and to create profiles of their general online behavior. Information collected by tracking cookies is commonly used to serve users with targeted online advertising.

Cookies Details

Back Button

Cookie List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Confirm My Choices

Reject All Accept All

Powered by Onetrust

Prompts

Zoetis Inc. (ticker ZTS), listed in United States.

Company History

Date Change Detail
Jul 30, 2018 Acquired Acquired Abaxis Inc (CIK 881890). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Zoetis Inc.

ETF Weight in ETF Shares Market value As of
DHLX 3.12% 37,826 $ 2.718M Jun 30, 2026
KAT 2.54% 229,949 $ 16.524M Jun 30, 2026
HCOW 2.50% 5,678 $ 408.021K Jun 30, 2026
GKAT 2.36% 52,519 $ 3.774M Jun 30, 2026
SMRI 2.32% 193,645 $ 16.17M Nov 18, 2026
DVGR 1.63% 3,277 $ 270K Nov 18, 2026
ABIG 1.54% 10,943 $ 910K Nov 18, 2026
BUSA 1.52% 63,151 $ 4.538M Jun 30, 2026
AQEC 1.45% 115,987 $ 8.335M Jun 30, 2026
CVAR 1.40% 7,761 $ 599.848K Jul 31, 2026
JDOC 1.30% 1,541 $ 128.643K Nov 17, 2026
CSTK 1.00% 22,814 $ 1.763M Jul 31, 2026
PY 0.82% 25,185 $ 1.81M Jun 30, 2026
DWSH short -0.81% -602 $ -50.255K Nov 17, 2026
DSTL 0.59% 175,017 $ 12.577M Jun 30, 2026
COPY 0.59% 31,936 $ 2.462M Aug 31, 2026
ESLV 0.52% 951 $ 73.503K Jul 31, 2026
WCEO 0.49% 632 $ 48.847K Jul 31, 2026
MID 0.46% 6,253 $ 482.106K Aug 31, 2026
PRAY 0.43% 4,663 $ 335.083K Jun 30, 2026
SEIQ 0.39% 36,438 $ 2.618M Jun 30, 2026
EHLS short -0.37% -2,383 $ -201.101K Nov 17, 2026
ESUM 0.33% 7,829 $ 605.103K Jul 31, 2026
GVLU 0.32% 9,947 $ 839.427K Nov 17, 2026
KNOW 0.27% 261 $ 18.755K Jun 30, 2026
DUHP 0.23% 538,902 $ 44.707M Nov 12, 2026
AVIE 0.22% 442 $ 37.3K Nov 16, 2026
JAVA 0.20% 182,206 $ 15.211M Nov 17, 2026
AVMC 0.17% 11,093 $ 936.138K Nov 16, 2026
VFVA 0.15% 18,179 $ 1.402M Aug 31, 2026
BAMG 0.15% 2,413 $ 186.042K Aug 31, 2026
CAPE 0.14% 4,610 $ 331.275K Jun 30, 2026
GSPY 0.13% 10,676 $ 900.948K Nov 17, 2026
VSLU 0.11% 8,163 $ 586.593K Jun 30, 2026
AVSU 0.10% 5,871 $ 495.454K Nov 16, 2026
AVMV 0.10% 9,708 $ 819.258K Nov 16, 2026
HELO 0.10% 54,749 $ 4.57M Nov 17, 2026
JUSA 0.09% 9,033 $ 754.075K Nov 17, 2026
XMAG 0.08% 2,081 $ 172.64K Nov 13, 2026
MPLY 0.08% 158 $ 12.212K Jul 31, 2026
IALT 0.07% 62,207 $ 5.25M Nov 16, 2026
AVUQ 0.07% 3,706 $ 312.749K Nov 16, 2026
MODL 0.06% 9,204 $ 661.399K Jun 30, 2026
TACU 0.06% 138 $ 11.646K Nov 17, 2026
ACVF 0.06% 1,125 $ 86.951K Jul 31, 2026
VOXP 0.05% 36 $ 2,782.44 Jul 31, 2026
DCOR 0.05% 257,196 $ 21.337M Nov 12, 2026
GDE 0.04% 2,685 $ 207.014K Aug 31, 2026
NTSX 0.04% 7,838 $ 563.239K Jun 30, 2026
HCMT 0.04% 2,917 $ 225.455K Jul 31, 2026
AVLC 0.04% 7,716 $ 651.153K Nov 16, 2026
DFSU 0.03% 9,950 $ 825.452K Nov 12, 2026
APUE 0.03% 10,193 $ 785.88K Aug 31, 2026
NTSD 0.03% 156 $ 11.21K Jun 30, 2026
AVUS 0.03% 60,145 $ 5.076M Nov 16, 2026
CSHP 0.02% 693 $ 58.482K Nov 16, 2026
DFUS 0.02% 51,040 $ 4.234M Nov 12, 2026
DFAC 0.02% 195,156 $ 16.19M Nov 12, 2026
DXUV 0.02% 11,431 $ 948.316K Nov 12, 2026
EBI 0.00% 133 $ 10.254K Aug 31, 2026
GEW 0.00% 53 $ 4,086.30 Aug 31, 2026
CORO 0.00% 261 $ 21.993K Nov 16, 2026